PROMO!
First order? Get 10% OFF with this code: 1storder
PROMO!
First order? Get 10% OFF with this code: 1storder
Our Product Categories
Ipamorelin is a synthetic peptide that belongs to the class of growth hormone secretagogues (GHS). It is designed to stimulate the pituitary gland to release growth hormone (GH). Ipamorelin is a pentapeptide, made of five amino acids arranged in a specific way to make it active.
Ipamorelin specifically targets growth hormone release without significantly affecting other hormones like cortisol or prolactin. This selectivity makes it ideal for research on growth hormone regulation and potential therapies.
In research, ipamorelin is studied for its potential to help build muscle, speed up recovery, and repair tissue. It’s also being studied for its potential anti-aging benefits, as growth hormone plays a crucial role in metabolism, cell regeneration, and immune function. In clinical settings, it’s typically administered through subcutaneous or intramuscular injections to ensure effective results.
Ipamorelin works by binding to the ghrelin receptor (GHS-R), which signals cells to release growth hormone. The mechanism involves activating the pituitary gland through pathways like protein kinase C (PKC) and phospholipase C (PLC), which promotes the release of growth hormone (GH) into the bloodstream.
It also helps to lower somatostatin, a hormone that normally inhibits GH. Unlike other growth hormone secretagogues, Ipamorelin does not impact other hormones, such as cortisol or prolactin, and therefore promotes a natural, steady release of GH. This mechanism then increases IGF-1 levels, leading to improved muscle growth, faster tissue repair, and enhanced overall metabolism.
Growth Hormone Release: Research has shown that Ipamorelin, a potent growth hormone secretagogue (GHS), stimulates GH release by acting on GHRP-like receptors with high efficacy and selectivity. Unlike other GHSs, ipamorelin does not significantly affect ACTH or cortisol levels, even at high doses, ensuring targeted GH release [1].
Studies show that its potency and efficacy are comparable to those of GHRP-6 in both in vitro and in vivo models, making it a promising candidate for treating GH deficiencies without undesired hormonal side effects [2].
Body Composition and Metabolism: Research suggests that Ipamorelin positively impacts body composition and metabolism by stimulating GH release, which promotes lipolysis and reduces adipose tissue. Studies show that GH-induced lipolysis enhances fat breakdown, particularly in metabolically active adipocytes, while improving insulin sensitivity and reducing lipotoxicity [3].
In hypogonadal and eugonadal males, ipamorelin has shown potential to counteract fat gain and muscle atrophy, improving overall body composition. Its targeted effects make it a promising adjunct therapy for metabolic and hormonal imbalances [4].
Bone Density: Research has demonstrated that Ipamorelin enhances bone density by stimulating growth hormone (GH) release, promoting bone mineral content (BMC) and formation. Studies in rats show ipamorelin increases tibial and vertebral BMC, primarily through bone growth and increased dimensions, while maintaining volumetric bone mineral density (BMD) [5].
Additionally, ipamorelin counteracts glucocorticoid-induced bone loss, significantly boosting periosteal bone formation rates. These findings highlight ipamorelin’s potential to support bone health and combat catabolic effects on skeletal integrity [6].
Gastrointestinal Function: Research suggests that Ipamorelin regulates inflammation and improves bowel function by stimulating ghrelin receptors, enhancing gastrointestinal motility. Clinical trials show ipamorelin reduces time to first tolerated meal in postoperative ileus (POI) patients, though not significantly [7].
In rodent models, repetitive dosing of ipamorelin accelerates colonic transit, increases fecal output, and improves food intake and weight gain after surgery [8]. These findings highlight ipamorelin’s potential to alleviate POI symptoms and support recovery of bowel function post-surgery.
 Neurocognitive Potential: Research has demonstrated that Ipamorelin, a ghrelin receptor agonist, offers neuroprotective benefits by activating GHS-R1a and inhibiting apoptotic pathways. Studies in Parkinson’s disease models show ghrelin, via GHS-R1a activation, reduces dopaminergic neuron loss, microglial activation, and pro-inflammatory molecules like TNF-alpha and IL-1beta.
It also suppresses matrix metalloproteinase-3 (MMP-3) expression in stressed neurons, indirectly deactivating microglia. These effects highlight ipamorelin’s potential as a therapeutic agent for neurodegenerative diseases by protecting neurons and reducing inflammation [9].
[1] J Ishida, M Saitoh, N Ebner, J Springer, et al (2020) Growth hormone secretagogues: history, mechanism of action, and clinical development – JCSM Communications, Volume 3, Issue 1, January/June 2020, Pages 25-37.
[2] K Raun, B S Hansen, N L Johansen, H Thøgersen, et al (1998) Ipamorelin, the first selective growth hormone secretagogue – European Journal of Endocrinology, 1998 Nov, Volume 139 (Issue 5), Pages 552-61.
[3] J J Kopchick, D E Berryman, V Puri, K Y Lee, et al (2019) The effects of growth hormone on adipose tissue: old observations, new mechanisms – Nature Reviews Endocrinology, 2019 Nov 28, Volume 16 (Issue 3), Pages 135–146.
[4] D K Sinha, A Balasubramanian, A J Tatem, J Rivera-Mirabal, et al (2020) Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males – Translational Andrology Urology, 2020 Mar, Volume 9 (Suppl 2), Pages S149–S159.
[5] J Svensson, S Lall, S L Dickson, B A Bengtsson, et al (2000) The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats – Journal of Endocrinology, 2000 Jun, Volume 165 (Issue 3), Pages 569-77.
[6] N.B. Andersen, K. Malml̦f, P.B. Johansen, T.T. Andreassen, et al (2001) The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats РGrowth Hormone & IGF Research, Volume 11, Issue 5, October 2001, Pages 266-272.
[7] D E Beck, W B Sweeney, and M D McCarter (2014) Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients – International Journal of Colorectal Disease, 2014 Dec, Volume 29 (Issue 12), Pages 1527-34.
[8] K Venkova, W Mann, R Nelson et al (2009) Efficacy of Ipamorelin, a Novel Ghrelin Mimetic, in a Rodent Model of Postoperative Ileus – The Journal of Pharmacology and Experimental Therapeutics, Volume 329, Issue 3, June 2009, Pages 1110-1116.
The answers to the most frequently asked questions about Ipamorelin.
Buy Ipamorelin Peptide Nasal Spray from Peptide Works. Available in 15ml and 30ml glass spray bottles, this non-invasive administration route offers a simple and effective option for consistent application.
Ipamorelin is a research peptide that stimulates the release of growth hormone in studies. Research shows it may support muscle growth, recovery, and fat metabolism. Scientists also study its potential effects on sleep quality, bone strength, and collagen production. More research is needed to understand its full benefits and safety.
Ipamorelin triggers the release of growth hormone, which supports tissue repair and regeneration. This process could, in theory, help maintain skin health and elasticity. However, research has not shown direct improvements in wrinkles or collagen from ipamorelin itself. Current evidence only confirms its role in stimulating growth hormone, not visible anti-aging effects.
Studies report that ipamorelin may cause mild effects such as temporary headache, dizziness or local irritation at the injection site during testing. Rare systemic effects have also been observed in experimental models. Data on its safety profile remain limited, and further controlled research is needed to define potential risks and tolerability.
Ipamorelin is not approved by the U.S. Food and Drug Administration (FDA) for medical or human use. In the United States, it is legal to purchase only for laboratory research. Laws and regulations can vary in other countries, where certain peptides may be classified or controlled differently. Always follow local rules before purchasing or handling.
The blog explores the synergistic benefits of combining Ipamorelin and CJC-1295 in peptide research. It highlights their complementary roles in growth hormone release, focusing on muscle recovery, fat metabolism, sleep quality and anti-aging. By comparing DAC and No DAC variations, the blog provides insights into their applications for natural hormone rhythms and sustained activity.
This blog compares Ipamorelin and Sermorelin, two growth hormone (GH) peptides, highlighting their unique mechanisms, benefits, and research applications. It explores Ipamorelin’s selective action for rapid GH release and Sermorelin’s natural hormone-mimicking effects. The blog also examines safety profiles, receptor pathways, and future advancements in GH peptide research for scientific studies.
This blog examines the science behind muscle-building peptides, focusing on their importance in research. It looks at how compounds such as Ipamorelin, CJC-1295, MGF, and MK-677 can help stimulate growth hormone release, increase IGF-1 production, and promote protein synthesis. When combined with amino acids and mechanical tension, these peptides give researchers valuable insight into the processes that drive muscle growth and recovery.
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Peptide Works website: https://peptide-works.com/ is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
